Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

Aug 22 2016

• By Derrick Gingery

Related Content

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

May 27 2015

Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device

May 26 2016

User Fee Goal Dates

Mar 07 2016

Novo's Diabetes Combo May Find Home With General Practitioners

May 25 2016

Sanofi's iGlarLixi: Two Formulations Raise FDA Red Flag On Dosing Errors

May 23 2016

Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

Jul 29 2016

Tracking The Priority Review Vouchers

Jul 27 2016

Diabetes Combination Studies Leave Market Challenges Unresolved

Jun 06 2016

Units, Clicks? Novel Diabetes Combos Need A Measurement

Jun 06 2016

Diabetes Combos: Novo, Sanofi May Need New Treatment Paradigm To Match Products

May 30 2016

Related Companies

Sanofi

Novo Nordisk A/S

Travere Therapeutics, Inc.

Additional Topics

United States Drug Review Safety Regulation Diabetic Care BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window